Categories
Markets

ACST Stock – (NASDAQ: ACST) is giving an update on the usage

ACST Stock – (NASDAQ: ACST) is giving an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of the “at the market” equity of its offering program.

As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement a “at the market” equity offering program under which Acasti might issue and market from time to time the common shares of its having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 huge number of. The ATM Shares had been marketed at prevailing market costs averaging US$1.0747 per share. No securities had been sold through the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with their services. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March five, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and often will provide the Company with extra flexibility in its ongoing review process to check out and evaluate strategic alternatives.

About Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescribed drugs making use of OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical proof of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for individuals with serious HTG.

Forward Looking Statements – ACST Stock

Statements in that press release which are not statements of current or historical truth constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking assertions include known and unknown risks, uncertainties, as well as other unknown components that may cause the particular outcomes of Acasti to be materially different from historical success or from any future outcomes expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, people are urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other related expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward looking statements, which speak just as of the date of this press release. Forward-looking statements in this press release include, but are not limited to, information or statements about Acasti’s strategy, succeeding operations as well as its review of strategic alternatives.

The forward looking statements contained in this specific press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area contained in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and on the investor aisle of Acasti’s website at www.acastipharma.com. Many forward looking statements in that press release are manufactured as of the date of this press release.

ACST Stock – Acasti doesn’t undertake to update some such forward-looking statements whether as a direct result of information which is brand new, future events or otherwise, except as required by law. The forward-looking assertions contained herein are also subject generally to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage

Leave a Reply

Your email address will not be published. Required fields are marked *